United Laboratories International (HKG:3933) unit The United Bio-Technology (Hengqing) dosed the first participant in a phase III clinical trial of UBT251 Injection in China, according to a Hong Kong bourse filing on Friday.
The study aims to evaluate the efficacy and safety of the drug in overweight participants or those with obesity.